Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent
NEW YORK, Nov. 12, 2013
NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB:
ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing
innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, today announced the appointment of Richard I. Steinhart to its board
of directors (Board). The Board also named Mr. Steinhart as Chairman of the
Board's Audit Committee and a member of the Board's Compensation Committee.
The Company's Chief Executive Officer, Dr. Kaushik Dave, said, "We are very
pleased to have Richard join our Board. His financial and industry expertise
complements our current, experienced Board members. He will add valuable
knowledge and guidance as we expand and develop our product pipeline."
"It's a great pleasure to be joining the Board of Actinium and to have the
opportunity to work with a talented team focused on developing treatments for
unmet medical needs in cancer," said Mr. Steinhart.
Mr. Steinhart has been employed by MELA Sciences, Inc, as their Vice
President, Finance and Chief Financial Officer, Treasurer and Secretary since
April 2006 and in April 2012, Mr. Steinhart received a promotion to Sr. Vice
President, Finance. From May 1992 until joining the MELA Sciences Mr.
Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a
boutique investment banking, venture capital, and management consulting firm
focused on healthcare and technology companies. Prior to Forest Street
Capital/SAE Ventures, he was Vice President and Chief Financial Officer of
Emisphere Technologies, Inc. Mr. Steinhart's other experience includes seven
years at CW Group, Inc., a venture capital firm focused on medical technology
and biopharmaceutical companies, where he was a General Partner and Chief
Financial Officer. Until December 2011, Mr. Steinhart served on the Board of
Manhattan Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman
of its Audit Committee. Mr. Steinhart began his career at Price Waterhouse,
now known as PricewaterhouseCoopers. He holds B.B.A. and M.B.A degrees from
Pace University and is a Certified Public Accountant (inactive).
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted
radiotherapy is based on its proprietary delivery platform for the therapeutic
utilization of alpha emitting actinium-225 and bismuth-213
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company
also develops other radiopharmaceuticals for select applications.
For more information:
Visit our web site www.actiniumpharmaceuticals.com
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.